|
1
|
Carlini V, Noonan DM, Abdalalem E, Goletti
D, Sansone C, Calabrone L and Albini A: The multifaceted nature of
IL-10: Regulation, role in immunological homeostasis and its
relevance to cancer, COVID-19 and post-COVID conditions. Front
Immunol. 14:11610672023. View Article : Google Scholar
|
|
2
|
Mocellin S, Panelli MC, Wang E, Nagorsen D
and Marincola FM: The dual role of IL-10. Trends Immunol. 24:36–43.
2003. View Article : Google Scholar
|
|
3
|
Saraiva M, Vieira P and O'Garra A: Biology
and therapeutic potential of interleukin-10. J Exp Med.
217:e201904182020. View Article : Google Scholar
|
|
4
|
Fujimura T, Kambayashi Y and Aiba S:
Crosstalk between regulatory T cells (Tregs) and myeloid derived
suppressor cells (MDSCs) during melanoma growth. Oncoimmunology.
1:1433–1434. 2012. View Article : Google Scholar
|
|
5
|
Pan Y, Yu Y, Wang X and Zhang T:
Tumor-associated macrophages in tumor immunity. Front Immunol.
11:5830842020. View Article : Google Scholar
|
|
6
|
Emmerich J, Mumm JB, Chan IH, LaFace D,
Truong H, McClanahan T, Gorman DM and Oft M: IL-10 directly
activates and expands tumor-resident CD8(+) T cells without de novo
infiltration from secondary lymphoid organs. Cancer Res.
72:3570–3581. 2012. View Article : Google Scholar
|
|
7
|
Guo Y, Xie YQ, Gao M, Zhao Y, Franco F,
Wenes M, Siddiqui I, Bevilacqua A, Wang H, Yang H, et al: Metabolic
reprogramming of terminally exhausted CD8+ T cells by
IL-10 enhances anti-tumor immunity. Nat Immunol. 22:746–756. 2021.
View Article : Google Scholar
|
|
8
|
Oft M: IL-10: Master switch from
tumor-promoting inflammation to antitumor immunity. Cancer Immunol
Res. 2:194–199. 2014. View Article : Google Scholar
|
|
9
|
Mannino MH, Zhu Z, Xiao H, Bai Q,
Wakefield MR and Fang Y: The paradoxical role of IL-10 in immunity
and cancer. Cancer Lett. 367:103–107. 2015. View Article : Google Scholar
|
|
10
|
Jankovic D, Kugler DG and Sher A: IL-10
production by CD4+ effector T cells: A mechanism for
self-regulation. Mucosal Immunol. 3:239–246. 2010. View Article : Google Scholar
|
|
11
|
Roncarolo MG, Gregori S, Bacchetta R,
Battaglia M and Gagliani N: The biology of T regulatory type 1
cells and their therapeutic application in immune-mediated
diseases. Immunity. 49:1004–1019. 2018. View Article : Google Scholar
|
|
12
|
Vence L, Palucka AK, Fay JW, Ito T, Liu
YJ, Banchereau J and Ueno H: Circulating tumor antigen-specific
regulatory T cells in patients with metastatic melanoma. Proc Natl
Acad Sci USA. 104:20884–20889. 2007. View Article : Google Scholar
|
|
13
|
Wang HY, Peng G, Guo Z, Shevach EM and
Wang RF: Recognition of a new ARTC1 peptide ligand uniquely
expressed in tumor cells by antigen-specific CD4+ regulatory T
cells. J Immunol. 174:2661–2670. 2005. View Article : Google Scholar
|
|
14
|
Bonertz A, Weitz J, Pietsch DHK, Rahbari
NN, Schlude C, Ge Y, Juenger S, Vlodavsky I, Khazaie K, Jaeger D,
et al: Antigen-specific Tregs control T cell responses against a
limited repertoire of tumor antigens in patients with colorectal
carcinoma. J Clin Invest. 119:3311–3321. 2009.
|
|
15
|
Yamada K, Masuda K, Ida S, Tada H, Bando
M, Abe K, Tatematsu KI, Sezutsu H, Oyama T, Chikamatsu K and Takeda
S: In vitro assessment of antitumor immune responses using tumor
antigen proteins produced by transgenic silkworms. J Mater Sci
Mater Med. 32:582021. View Article : Google Scholar
|
|
16
|
Tada H, Takahashi H, Yamada K, Masuda K,
Nagata Y, Uchida M, Shino M, Ida S, Mito I, Matsuyama T, et al:
Dynamic alterations of circulating T lymphocytes and the clinical
response in patients with head and neck squamous cell carcinoma
treated with nivolumab. Cancer Immunol Immunother. 71:851–863.
2022. View Article : Google Scholar
|
|
17
|
Nagorsen D, Keilholz U, Rivoltini L,
Schmittel A, Letsch A, Asemissen AM, Berger G, Buhr HJ, Thiel E and
Scheibenbogen C: Natural T-cell response against MHC class I
epitopes of epithelial cell adhesion molecule, her-2/neu, and
carcinoembryonic antigen in patients with colorectal cancer. Cancer
Res. 60:4850–4854. 2000.
|
|
18
|
Duray A, Demoulin S, Hubert P, Delvenne P
and Saussez S: Immune suppression in head and neck cancers: A
review. Clin Dev Immunol. 2010:7016572010.
|
|
19
|
Kostecki KL, Iida M, Crossman BE, Salgia
R, Harari PM, Bruce JY and Wheeler DL: Immune escape strategies in
head and neck cancer: Evade, resist, inhibit, recruit. Cancers
(Basel). 16:3122024. View Article : Google Scholar
|
|
20
|
Elmusrati A, Wang J and Wang CY: Tumor
microenvironment and immune evasion in head and neck squamous cell
carcinoma. Int J Oral Sci. 13:242021. View Article : Google Scholar
|
|
21
|
Heusinkveld M, Goedemans R, Briet RJP,
Gelderblom H, Nortier JWR, Gorter A, Smit VTHBM, Langeveld APM,
Jansen JC and van der Burg SH: Systemic and local human
papillomavirus 16-specific T-cell immunity in patients with head
and neck cancer. Int J Cancer. 131:E74–E85. 2012. View Article : Google Scholar
|
|
22
|
Hoffmann TK, Donnenberg AD, Finkelstein
SD, Donnenberg VS, Friebe-Hoffmann U, Myers EN, Appella E, DeLeo AB
and Whiteside TL: Frequencies of tetramer+ T cells specific for the
wild-type sequence p53(264–272) peptide in the circulation of
patients with head and neck cancer. Cancer Res. 62:3521–3529.
2002.
|
|
23
|
Hoffmann TK, Nakano K, Elder EM, Dworacki
G, Finkelstein SD, Appella E, Whiteside TL and DeLeo AB: Generation
of T cells specific for the wild-type sequence p53(264–272) peptide
in cancer patients: Implications for immunoselection of epitope
loss variants. J Immunol. 165:5938–5944. 2000. View Article : Google Scholar
|
|
24
|
Ikeguchi M, Hatada T, Yamamoto M, Miyake
T, Matsunaga T, Fukumoto Y, Yamada Y, Fukuda K, Saito H and Tatebe
S: Serum interleukin-6 and −10 levels in patients with gastric
cancer. Gastric Cancer. 12:95–100. 2009. View Article : Google Scholar
|
|
25
|
Wang H, Wang L, Chi PD, Wang WD, Chen XQ,
Geng QR, Xia ZJ and Lu Y: High level of interleukin-10 in serum
predicts poor prognosis in multiple myeloma. Br J Cancer.
114:463–468. 2016. View Article : Google Scholar
|
|
26
|
De Vita F, Orditura M, Galizia G, Romano
C, Roscigno A, Lieto E and Catalano G: Serum interleukin-10 levels
as a prognostic factor in advanced non-small cell lung cancer
patients. Chest. 117:365–373. 2000. View Article : Google Scholar
|
|
27
|
Cortes JE, Talpaz M, Cabanillas F, Seymour
JF and Kurzrock R: Serum levels of interleukin-10 in patients with
diffuse large cell lymphoma: Lack of correlation with prognosis.
Blood. 85:2516–2520. 1995. View Article : Google Scholar
|
|
28
|
Evans C, Morrison I, Heriot AG, Bartlett
JB, Finlayson C, Dalgleish AG and Kumar D: The correlation between
colorectal cancer rates of proliferation and apoptosis and systemic
cytokine levels; plus their influence upon survival. Br J Cancer.
94:1412–1419. 2006. View Article : Google Scholar
|
|
29
|
Green VL, Irune E, Prasai A, Alhamarneh O,
Greenman J and Stafford ND: Serum IL10, IL12 and circulating
CD4+CD25high T regulatory cells in relation to long-term clinical
outcome in head and neck squamous cell carcinoma patients. Int J
Oncol. 40:833–839. 2012.
|
|
30
|
Kim Y, Yang H, Lee WS, Cheon J, Sang YB,
Kang B, Chon HJ and Kim C: High levels of baseline serum IL-10 are
associated with reduced clinical benefit from first-line immune
checkpoint inhibitor therapy in advanced renal cell carcinoma. J
Cancer. 14:935–942. 2023. View Article : Google Scholar
|
|
31
|
Giunta EF, Barra G, De Falco V, Argenziano
G, Napolitano S, Vitale P, Zanaletti N, Terminiello M, Martinelli
E, Morgillo F, et al: Baseline IFN-γ and IL-10 expression in PBMCs
could predict response to PD-1 checkpoint inhibitors in advanced
melanoma patients. Sci Rep. 10:176262020. View Article : Google Scholar
|
|
32
|
Rutz S and Ouyang W: Regulation of
interleukin-10 expression. Adv Exp Med Biol. 941:89–116. 2016.
View Article : Google Scholar
|
|
33
|
Huo JL, Wang YT, Fu WJ, Lu N and Liu ZS:
The promising immune checkpoint LAG-3 in cancer immunotherapy: From
basic research to clinical application. Front Immunol.
13:9560902022. View Article : Google Scholar
|
|
34
|
Joller N and Kuchroo VK: Tim-3, Lag-3, and
TIGIT. Curr Top Microbiol Immunol. 410:127–156. 2017.
|
|
35
|
Gagliani N, Magnani CF, Huber S, Gianolini
ME, Pala M, Licona-Limon P, Guo B, Herbert DR, Bulfone A, Trentini
F, et al: Coexpression of CD49b and LAG-3 identifies human and
mouse T regulatory type 1 cells. Nat Med. 19:739–746. 2013.
View Article : Google Scholar
|
|
36
|
Matsuzaki J, Gnjatic S, Mhawech-Fauceglia
P, Beck A, Miller A, Tsuji T, Eppolito C, Qian F, Lele S, Shrikant
P, et al: Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are
negatively regulated by LAG-3 and PD-1 in human ovarian cancer.
Proc Natl Acad Sci USA. 107:7875–7880. 2010. View Article : Google Scholar
|
